Jeffrey Bennett, AAN 2022: Challenges in the treatment of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder
Aquaporin 4-immunoglobulin G (AQP4-IgG) plays a major role in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). Prof. Jeffrey Bennett (University of Colorado School of Medicine, Aurora, CO, USA) discusses the challenges in the treatment of NMOSD.
- What are the challenges in the treatment of neuromyelitis optica spectrum disorder (NMOSD)? (0:14)
- What is the role of aquaporin 4-immunoglobulin G (AQP4-IgG) in the pathogenesis of NMOSD, and what percentage of patients are seropositive for this antibody? (1:17)
Disclosures: Jeffrey Bennett is/has been a consultant for Roche/Genentech, Chugai Pharmaceuticals, Horizon, Mitsubishi-Tanabe, Reistone Bio, Abbvie, Clene Neuroscience, Alexion-AstraZeneca Rare Disease, and Beigene; and has received grant/research support from National Institutes of Health, Novartis, Mallinckrodt Pharmaceuticals, and Alexion-AstraZeneca Rare Disease; and is on the advisory board for Roche/Genentech, and Alexion-AstraZeneca Rare Disease.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Rare Diseases
Lisa Sarfaty: Help support Rare Disease Day
Our society partner, NORD (The National Organization for Rare Disorder) has planned several initiatives to support this year’s Rare Disease Day on 28 February. These activities are aimed at raising awareness about rare diseases and the challenges faced by people living with these conditions. In this video, Lisa Sarfaty, NORD’s VP of Communication and Engagement, […]
Lisa Sarfaty: Exploring and addressing inequities in rare diseases
Rare diseases can present numerous challenges for those living with these conditions and the healthcare professionals caring for them. In this interview we discuss some of these with Lisa Sarfaty, VP of Communication and Engagement for NORD (The National Organization for Rare Disorders) and explore ways in which they could be tackled. Questions Could you […]
Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis – ADAPT trial findings
The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. Questions: 1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!